Seeking Alpha
08 May 2026, 14:58 UTC · 18w ago
Verdict
Headline leans bearish. We score IOVA −0.80 across two claims.
Score confirms the headline.
IOVA score
−0.80
More negative than 86% of ticker scores this week
Price reaction
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by
What the story claims
2 claims · scored −1 bearish … +1 bullish
Iovance Biotherapeutics shares declined over 13% following its Q1 earnings announcement.
So whatA double-digit price drop immediately following earnings indicates a significant negative market reaction to the company's financial performance or guidance.
More negative than 91% of claims this week
Iovance Biotherapeutics markets Amtagvi, a TIL therapy for advanced melanoma.
Continue reading
5 related stories
More positive than 47% of claims this week
Which stocks this story touches
More negative than 86% of ticker scores this week
Shares declined over 13% following Q1 earnings results due to investor concerns about near-term performance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
1h ago
Price reaction
Expected −0.80Actual +142.3%
Price is moving against the score
87 sessions since publication. $8.60 vs $3.55 close before publication (May 7). Not market-adjusted.
IOVA chart →
